2022年以来，本市通过设立首都医疗科技成果转化公益基金、成立首都汇智医疗科技成果转化研究院， 开展医疗卫生机构医学创新和成果转化改革试点，目前公益基金会已累计募集资金超1.5亿元，支持了 两批5家试点医院的24个项目，产出29款转化产品与诊疗技术。殷勇来到转化研究院，听取公益基金 会、转化研究院运行机制及工作成效汇报，察看部分试点项目展品，了解成果转化阶段性进展，指出， 要结合前期试点改革实践，充分发挥公益基金会、转化研究院作用，持续深化医学创新和成果转化改 革，抓紧研究探索建立市场导向、利益共享、多方共赢的成果转化激励机制，打造可持续的商业模式， 更好激发各方参与的积极性。总结推广改革试点经验，稳妥扩大试点范围，更好链接医院、高校、科研 院所、投资机构等各方资源，提升成果转化质效，推动更多转化产品落地应用，切实增进群众健康福 祉。 转自：北京日报客户端 1月8日上午，市委副书记、市长殷勇到海淀区调研医疗科技成果转化和人工智能产业发展工作。他强 调，今年是"十五五"开局之年，要深入贯彻中央经济工作会议精神，落实市委十三届八次全会部署，充 分发挥北京教育科技人才优势，着力攻关关键核心技术、创新拓展应用场景、打 ...

人民财讯1月9日电，据悉，四川明确脑机接口医疗服务价格，置入费最高6583元/次。企查查APP显 示，近期，成都、武汉、上海、北京等多地医院公开脑机接口专利。其中，四川省医学科学院.四川省 人民医院"一种用于圆弧形脑机接口电池的固态电解质膜的制备方法"专利可满足不同脑机接口场景需 求；华中科技大学同济医学院附属同济医院"一种颅骨下硬膜外微侵袭式柔性脑机接口电极"专利中脑机 接口电极为柔性线型，可以植入至脑膜中动脉，无需开颅手术，不必担心长期植入后的炎症反应、免疫 刺激、生物相容性、脑组织损伤等不利因素；复旦大学附属中山医院"一种基于脑机接口的硬膜外电刺 激下肢康复系统与方法"专利可用于脊髓损伤患者术后康复；首都医科大学宣武医院"植入式脑机接口控 制脊髓电刺激的患者改善效果分析方法"专利涉及医疗康复技术领域，可有效去除脑电信号中的SCS电 刺激干扰、EXS电机噪声及生理噪声。 ...

1月8日，国家医保局办公室正式发布《关于大力推进刷脸支付、一码支付、移动支付、信用支付等便捷 支付工作的通知》，聚焦群众看病缴费"多次排队""排长队"等堵点痛点，明确用3年左右时间全面建成 医保便捷支付体系。值得关注的是，德生科技（002908）深耕多年的"就医无感支付"服务，其创新实践 与政策导向高度契合，凭借技术实力与服务成效成为医保数字化转型的核心参与者。 技术与服务的双重优势，也为德生科技赢得了权威认可。在刚刚落幕的2025全国智慧医保大赛中，由德 生科技申报的"就医无感支付"项目，从180个决赛项目中脱颖而出，斩获全国总决赛一等奖殊荣。该赛 事由国家医保局和上海市政府联合主办，其奖项含金量彰显了行业对德生科技在医保数字化领域创新能 力与实践成效的高度肯定。 此次医保便捷支付政策的全面推进，为公司业务拓展提供了重要契机。未来，德生科技将持续以"数据 +场景"双轮驱动，依托成熟的技术方案与布局经验，加速"就医无感支付"在更多地区落地，助力医保便 捷支付体系全国建成，推动医疗服务向数字化、智能化深度跃迁。 总体来说，公司在AI医疗应用方面的布局，会以建设全医院数字化底座为基础，通过AI算法提升医疗 机构服 ...

Group 1 - The core viewpoint of the article highlights significant developments in various companies and industries, including IPOs, leadership changes, and market strategies [2][4][15] Group 2 - Zhiyuan AI went public on January 8, 2026, with a goal to become a leading global model enterprise by 2026, as stated by its founder and chief scientist, Tang Jie [2] - Vanke A announced the resignation of Yu Liang due to retirement, effective January 8, 2026, marking a significant leadership change in the company [4] - The founder's family of Maogeping plans to reduce their stake by 3.51%, amounting to approximately 1.41 billion HKD, to improve personal finances and invest in the beauty industry [4][7] Group 3 - Xiaomi's Lei Jun announced a significant investment in R&D, committing 200 billion CNY over the next five years to enhance core technologies, including AI and chips [7] - Multiple car manufacturers are launching promotional activities to counter the impact of new electric vehicle purchase taxes, with Tesla and GAC Group leading the charge [8] - Alphabet Inc. has surpassed Apple in market capitalization, becoming the second-largest company globally, reflecting its strong position in the AI sector [8] Group 4 - JD.com established the "Chameleon Business Unit" to accelerate the commercialization of AI technologies, with new AI products set to launch soon [13] - Alibaba Cloud introduced a multimodal interaction development kit aimed at AI hardware, integrating various foundational models for diverse applications [20] - Ford plans to launch an L3 level driving assistance system by 2028, initially in a new affordable electric pickup truck [21]

一、本次股份被冻结基本情况 上海润达医疗科技股份有限公司（以下简称"公司"）于近日获悉股东刘辉先生、朱文怡女士所持有公司 的部分股份被冻结，具体情况如下： ■ 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 刘辉先生持有公司股份31,528,771股，占公司总股本的5.22%。本次冻结的股份数为9,000,000股，累计 冻结的股份数为11,904,000股，占其持股总数的37.76%，占公司总股本的1.97%。 ● 朱文怡女士持有公司股份31,158,509股，占公司总股本的5.16%。本次冻结的股份数为9,000,000股，累 计冻结的股份数为9,000,000股，占其持股总数的28.88%，占公司总股本的1.49%。 ● 刘辉先生及朱文怡女士为一致行动人，截至本公告日，两人合计持有公司股份62,687,280股，占公司 总股本10.38%。合计冻结的股份数为20,904,000股，占持股总数的33.35%，占公司总股本的3.46%。 注：公司可转债处于 ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in iFlytek Medical Technology (02506.HK) by 3,500 shares on January 8, with a total net reduction of 193,900 shares over the last five trading days [1] - Over the past 20 trading days, there have been 11 days of net reductions in southbound fund holdings, totaling 215,500 shares [1] - As of now, southbound funds hold 3,728,700 shares of iFlytek Medical Technology, which represents 4.82% of the company's total issued ordinary shares [1] Group 2 - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled medical solutions in China [1] - The company's business lines include grassroots medical services, hospital services, patient services, and regional management platform solutions [1] - The grassroots medical services line consists of intelligent medical assistants and chronic disease management, while the hospital services line includes smart hospital solutions and diagnostic assistance [1]

Core Viewpoint - The recent surge in brain-computer interface (BCI) concept stocks has led to significant price increases for companies like Innovent Medical and Nanjing Panda, while regulatory scrutiny has emerged due to incomplete and inaccurate disclosures from companies like YHLO and Injoinic [1][6]. Group 1: Company Developments - YHLO announced a strategic cooperation framework agreement with Shenzhen Brain Machine Starlink Technology Co., focusing on product development, market promotion, and equity investment [3]. - Injoinic has entered the BCI chip market with its IPA1299 chip, designed for high-precision measurement of human bioelectrical signals, suitable for BCI applications [4][5]. - YHLO's main business involves the development, production, and sales of in vitro diagnostic instruments and related reagents, while Injoinic specializes in power management and mixed-signal SoC chips [4][5]. Group 2: Market Reactions - Following the announcements, Injoinic's stock price increased by 12.74% from January 5 to 7, while YHLO's stock rose by 6.52% on the day of its announcement, with trading volume up by 299% [5]. - Both companies faced regulatory attention from the Shanghai Stock Exchange due to the need for more accurate and complete disclosures regarding their BCI-related activities [6]. Group 3: Financial Performance - YHLO reported a revenue of approximately 1.287 billion yuan for the first three quarters of 2025, a year-on-year decline of 7.69%, with a net profit of about 60.42 million yuan, down 72.36% [7]. - In contrast, Injoinic experienced growth in both revenue and net profit, with the latter reaching approximately 114 million yuan, a year-on-year increase of 28.54% [7].

Group 1 - Fosun International's subsidiary, Shanghai Yiyao Technology Co., Ltd., has initiated the IPO process, aiming to expand its capital footprint in the A-share market [1][3] - Under the leadership of Guo Guangchang, Fosun has evolved into an innovation-driven global family consumption industry group, focusing on a happiness ecosystem centered around health, happiness, and wealth [1][4] - Currently, Fosun controls six A-share listed companies and four Hong Kong listed companies, with four of the A-share companies having a market capitalization exceeding 100 billion [1][6] Group 2 - The performance of Fosun's listed companies shows significant divergence, with six companies reporting a decline in net profit, reflecting operational pressures in certain sectors [1][8] - In the first three quarters of 2025, six A-share companies reported revenues exceeding 2 billion, with Shanghai Steel Union leading at approximately 57.32 billion [8] - Among the A-share companies, only Fosun Pharma and Shanghai Steel Union reported year-on-year growth in net profit, while others, including Yuyuan and Hainan Mining, experienced declines [8][9] Group 3 - Yiyao Technology, established in July 2018, focuses on providing high-tech solutions across various intelligent manufacturing sectors, including automotive and food automation [3][4] - Fosun's total assets exceeded 796.5 billion as of December 31, 2024, with a significant portion of revenue coming from international operations [4][6] - The group is shifting its strategy from diversification to deepening its core sectors, particularly in health and intelligent manufacturing, to optimize capital structure and enhance cash flow [7]

【环球网科技综合报道】1月8日消息，近日，波克科技旗下波克医疗推出的 BOKE STARS 注意力评估 软件成功获批NMPA二类医疗器械注册证，成为国内首款获此认证的游戏化儿童注意力评估软件。 该产品以游戏化交互完成儿童注意力功能的客观量化评估，并在多家知名三甲/儿童专科与妇幼医疗机 构完成临床研究验证；同时，依托独立软件形态，具备向社区、校园等场景拓展的可复制性。 据了解，我国目前约有 2300 多万 4-18 岁注意缺陷多动冲动障碍（ADHD）患者，学龄期患儿中 70% 的症状会持续至青春期，30%-50% 会延续到成年期，常伴随学习障碍、情绪障碍等问题，严重影响患 者的学习与生活。早期识别与干预对这类神经发育障碍疾病的管理至关重要，但当前市场上的同类评估 产品多以"软件 + 专用硬件"的一体化形态存在，场景局限于院内，难以下沉至社区、校园等广泛筛查与 随访场景，且适配儿童认知特点的产品尤为稀缺。 作为独立软件形态的二类医疗器械， BOKE STARS 基于经典 CPT（持续性操作测试）范式，采用游戏 化医疗的方式，呈现卡通化美术风格与任务化流程，契合儿童认知习惯，通过标准化视觉与听觉双通道 刺激任务，可 ...

Core Viewpoint - The article discusses the integration of 82 medical service pricing items related to the nervous system by the Sichuan Provincial Medical Insurance Bureau, including the pricing for brain-machine interface medical services, which will take effect on April 30 this year, with the highest implantation fee set at 6,583 yuan per instance [3][4]. Group 1 - The Sichuan Provincial Medical Insurance Bureau has issued a notification to consolidate 82 pricing items for nervous system medical services [3][4]. - The government-guided price for brain-machine interface services includes a maximum implantation fee of 6,583 yuan per instance [3][4]. - The pricing integration aims to clarify the medical insurance payment categories for these services [3][4]. Group 2 - The article lists various companies involved in the brain-machine interface and related technologies, including innovative medical firms such as Xinhua Medical, Yanjian Technology, and others [4]. - The integration of pricing is expected to impact companies engaged in brain signal acquisition and neuro-rehabilitation technologies [4].